Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSD1UN)

Drug Name
Bevacizumab Drug Info
Synonyms Bevacizumab (ophthalmic slow-release tissue tablet)
Indication
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [1]
Adult acute monocytic leukemia Approved [2]
Biliary tract cancer 2C17 Approved [3]
Childhood acute megakaryoblastic leukemia Approved [2]
Cholangiocarcinoma 2C12.10 Approved [4]
Colon adenocarcinoma Approved [5]
Colorectal carcinoma Approved [6]
Esophageal disorder Approved [7]
Glioblastoma 2A00 Approved [8]
Glioblastoma of brain 2A00.00 Approved [9]
Hemangioblastoma Approved [10]
Intracranial meningioma Approved [11]
Lung adenocarcinoma Approved [12]
Malignant epithelial tumor of ovary Approved [13]
Metastatic colorectal cancer 2B91 Approved [14]
Non-small-cell lung cancer 2C25.Y Approved [15]
Rectal adenocarcinoma 2B92 Approved [16]
Von hippel-lindau disease 5A75 Approved [17]
Colorectal cancer 2B91.Z Phase 3 [18]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [19]
Brain metastases 2D50 Phase 2 [18]
Lung cancer 2C25.0 Phase 1 [18]
Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
Ovarian cancer 2C73 Application submitted [20]
Adult glioblastoma Investigative [21]
Colon cancer 2B90.Z Investigative [22]
Fallopian tube cancer 2C74 Investigative [23]
Hereditary hemorrhagic telangiectasia LA90.00 Investigative [24]
Lung large cell carcinoma Investigative [25]
Cross-matching ID
TTD Drug ID
DMSD1UN

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Vascular endothelial growth factor A (VEGFA) TTOHSBA VEGFA_HUMAN Inhibitor [26]
HUMAN vascular endothelial growth factor (VEGF) TT140V6 VEGFA_HUMAN; VEGFB_HUMAN; VEGFC_HUMAN; VEGFD_HUMAN Inhibitor [19]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 8.544 6.927 7.253 7.839
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Adenocarcinoma
ICD Disease Classification 2D40
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Vascular endothelial growth factor A (VEGFA) DTT VEGFA 3.61E-01 0.15 0.47
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Bevacizumab in metastatic small-bowel adenocarcinoma: A systematic review and meta-analysis. Rare Tumors. 2019 May 14;11:2036361318825413.
2 A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
3 Angiogenesis in biliary tract cancer: targeting and therapeutic potential. Expert Opin Investig Drugs. 2021 Apr;30(4):411-418.
4 Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021 May 1;19(5):541-565.
5 Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer. Immunotherapy. 2023 Feb;15(3):127-133.
6 Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 2015 May;16(5):499-508.
7 Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther. 2020 Oct 7;5(1):229.
8 Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 1;27(28):4733-40.
9 Synchronous glioblastoma and brain metastases: illustrative case. J Neurosurg Case Lessons. 2022 Mar 21;3(12):CASE21714.
10 Intra-arterial Bevacizumab for Posterior Fossa Hemangioblastoma. Cureus. 2022 Dec 17;14(12):e32624.
11 The controversial role of Bevacizumab in the treatment of patients with intracranial meningioma: a comprehensive literature review. Expert Rev Anticancer Ther. 2020 Mar;20(3):197-203.
12 International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011 Feb;6(2):244-85.
13 Gynecologic cancer in pregnancy. Gynecol Oncol. 2020 Jun;157(3):799-809.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
15 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50.
16 Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as?preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term?results. BMC Cancer. 2020 Nov 27;20(1):1164.
17 89Zr-Bevacizumab PET Visualizes Disease Manifestations in Patients with von Hippel-Lindau Disease. J Nucl Med. 2016 Aug;57(8):1244-50.
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 ClinicalTrials.gov (NCT04275414) Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia (BEST-CP)
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
21 Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017 Nov 16;377(20):1954-1963.
22 Colon cancer. Crit Rev Oncol Hematol. 2010 May;74(2):106-33.
23 OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012 Jun 10;30(17):2039-45.
24 Hereditary hemorrhagic telangiectasia: diagnosis and management from the hematologist's perspective. Haematologica. 2018 Sep;103(9):1433-1443.
25 Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008 May;83(5):584-94.
26 FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.